ACE-031
Also known as ACVR2B-Fc, Myostatin Inhibitor
A fusion protein combining the activin IIB receptor with antibody Fc domain. Phase II trials in Duchenne MD showed significant muscle mass increase but were halted due to nosebleeds and gum bleeding.
Regulatory Pathway
Dosing Protocol
Typical Dose
0.5-3 mg/kg every 2 weeks (from discontinued trials)
Frequency
Every 2 weeks (research protocol)
Duration
Trials discontinued
Timing & Administration
Administer via Subcutaneous injection. Frequency: Every 2 weeks (research protocol).
Popular Uses
Mechanism of Action
Acts as a decoy receptor, binding and neutralizing myostatin, GDF11, and activins to promote muscle growth.
Research Summary
Evidence level: animal studies. Clinical status: Development halted - Safety concerns.
Side Effects & Safety
Important Warnings
- Clinical trials discontinued due to bleeding safety concerns
- Broad ligand binding may cause unwanted vascular effects.
References
No references available.
Related Peptides
Browse all →A neuropeptide that plays a critical role in initiating puberty and regulating the reproductive hormone axis.
View profileA mitochondria-derived peptide that regulates metabolic homeostasis, discovered in 2015 and studied for insulin sensitivity, exercise capacity, and aging effects.
View profileA naturally occurring peptide hormone essential for social bonding, childbirth, and lactation. Under investigation for autism, anxiety, and social disorders.
View profile